Tenofovir Alafenamide Fumarate
FDA-approved product (tablet, oral), marketed as Tenofovir Alafenamide, Tenofovir Alafenamide Fumarate, Vemlidy.
- Registered studies
- 50+
- Lab records
- 0
- Pathogens at ≥40%
- 2 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Chronic hepatitis B virus infection
- Hepatitis B virus infection
- HIV infection
- HIV-1 infection
- Viral disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Nucleoside and nucleotide reverse transcriptase inhibitors
- Anti-infective classification
- Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF13
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA35.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- E. coli42.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis61.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Tenofovir Alafenamide Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- Pafolacianine SodiumExisting use: Other diagnostic agents61.4% AI-predicted activityagainst E. coli1 registered study
- LinaclotideExisting use: Constipation, Constipation disorder, Irritable bowel syndrome60.5% AI-predicted activityagainst E. coli50+ registered studies
- PlecanatideExisting use: Constipation60.1% AI-predicted activityagainst E. coli15 registered studies
- Terazosin HydrochlorideExisting use: Benign prostatic hyperplasia60.0% AI-predicted activityagainst E. coli41 registered studies
- Leuprolide AcetateExisting use: Central precocious puberty, Metastatic prostate cancer, Neoplasm and 4 more59.6% AI-predicted activityagainst E. coli50+ registered studies
- Trilaciclib DihydrochlorideExisting use: Small cell lung carcinoma59.6% AI-predicted activityagainst E. coli2 registered studies
- Gonadorelin AcetateExisting use: Gonadotropin-releasing hormones, Tests for fertility disturbances59.5% AI-predicted activityagainst E. coli50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more59.4% AI-predicted activityagainst E. coli5 registered studies
- PalbociclibExisting use: Breast cancer, Breast carcinoma, Breast neoplasm and 3 more59.1% AI-predicted activityagainst E. coli50+ registered studies
- TemsirolimusExisting use: Cancer, Clear cell renal carcinoma, Mantle cell lymphoma and 2 more59.0% AI-predicted activityagainst E. coli50+ registered studies
- Angiotensin Ii AcetateExisting use: Cardiovascular disease, Hypotension, Septic shock and 1 more58.8% AI-predicted activityagainst E. coli10 registered studies
- Terlipressin AcetateExisting use: Hepatorenal syndrome, Kidney failure, Renal insufficiency58.8% AI-predicted activityagainst E. coli7 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection
NCT03425994 · start 2018-02-06
Registered record
- Registry ID
- NCT03425994
- Conditions
- Chronic Hepatitis B in HIV Patient; Kidney Injury; Bone Diseases
- Interventions
- Elvitegravir/Cobicistat/Emtricitabine
- Study type
- OBSERVATIONAL
- Phase
- Not recorded
- Registry status
- Unknown
- Start
- 2018-02-06
- Completion
- 2019-10-11
- Enrolment
- 275
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis B in HIV Patient; Kidney Injury; Bone DiseasesInterventionElvitegravir/Cobicistat/EmtricitabinePhaseNot recordedRegistry statusUnknownA Pharmacokinetic Evaluation of Tenofovir/Emtricitabine as HIV Pre-Exposure Prophylaxis in Transgender Women
NCT03270969 · start 2018-01-05
Registered record
- Registry ID
- NCT03270969
- Conditions
- HIV Prevention
- Interventions
- Tenofovir Disoproxil Fumarate/Emtricitabine
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2018-01-05
- Completion
- 2018-09-10
- Enrolment
- 15
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV PreventionInterventionTenofovir Disoproxil Fumarate/EmtricitabinePhasePhase 1Registry statusCompletedChange of Renal Function and Bone Mineral Density in CHB Patients Switch From TDF to TAF vs. Maintaining TDF
NCT03356834 · start 2017-12-01
Registered record
- Registry ID
- NCT03356834
- Conditions
- Chronic Hepatitis B
- Interventions
- Tenofovir alafenamide(TAF); Tenofovir disoproxil fumarate(TDF)
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2017-12-01
- Completion
- 2024-10-31
- Enrolment
- 575
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis BInterventionTenofovir alafenamide(TAF); Tenofovir disoproxil fumarate(TDF)PhasePhase 4Registry statusCompletedCarvedilol for Prevention of Esophageal Varices Progression
NCT03736265 · start 2017-10-09
Registered record
- Registry ID
- NCT03736265
- Conditions
- Cirrhosis, Liver; Portal Hypertension
- Interventions
- Carvedilol
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Unknown
- Start
- 2017-10-09
- Completion
- 2022-12-30
- Enrolment
- 240
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionCirrhosis, Liver; Portal HypertensionInterventionCarvedilolPhaseNot applicableRegistry statusUnknownSwitching to a Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Adults Who Are Virologically Suppressed
NCT03110380 · start 2017-06-12
Registered record
- Registry ID
- NCT03110380
- Conditions
- HIV-1-infection
- Interventions
- B/F/TAF; F/TAF; DTG; DTG Placebo; F/TAF Placebo; B/F/TAF Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-06-12
- Completion
- 2021-02-10
- Enrolment
- 567
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1-infectionInterventionB/F/TAF; F/TAF; DTG; DTG Placebo +2 morePhasePhase 3Registry statusCompletedRIFT: Effect of Rifampicin on Plasma PK of FTC, TAF and Intracellular TFV-DP & FTC-TP
NCT03186482 · start 2017-06-01
Registered record
- Registry ID
- NCT03186482
- Conditions
- HIV
- Interventions
- Descovy® (TAF/FTC); Viread® (TDF); Rifadin® (Rifampicin)
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2017-06-01
- Completion
- 2018-01-10
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIVInterventionDescovy® (TAF/FTC); Viread® (TDF); Rifadin® (Rifampicin)PhasePhase 1Registry statusCompletedEvaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis
NCT02998320 · start 2017-03-10
Registered record
- Registry ID
- NCT02998320
- Conditions
- HIV Risk
- Interventions
- Genvoya
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2017-03-10
- Completion
- 2018-09-30
- Enrolment
- 101
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV RiskInterventionGenvoyaPhasePhase 3Registry statusCompletedPK and PD Study of Oral F/TAF for HIV Prevention
NCT02904369 · start 2016-10-06
Registered record
- Registry ID
- NCT02904369
- Conditions
- HIV
- Interventions
- Emtricitabine; Tenofovir alafenamide; Tenofovir disoproxil
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Completed
- Start
- 2016-10-06
- Completion
- 2017-11-21
- Enrolment
- 73
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIVInterventionEmtricitabine; Tenofovir alafenamide; Tenofovir disoproxilPhasePhase 1Registry statusCompletedEfficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant
NCT02862548 · start 2016-09-16
Registered record
- Registry ID
- NCT02862548
- Conditions
- Chronic Hepatitis B
- Interventions
- TAF; TDF; Other approved antivirals
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2016-09-16
- Completion
- 2021-05-05
- Enrolment
- 51
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionChronic Hepatitis BInterventionTAF; TDF; Other approved antiviralsPhasePhase 2Registry statusCompletedHIV Drug Switch Followed by HCV Therapy in HIV-HCV Co-Infection
NCT02660905 · start 2016-04
Registered record
- Registry ID
- NCT02660905
- Conditions
- Human Immunodeficiency Virus; Hepatitis C, Chronic
- Interventions
- E/C/F/TAF; Ledipasvir-Sofosbuvir
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-04
- Completion
- 2018-06
- Enrolment
- 25
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHuman Immunodeficiency Virus; Hepatitis C, ChronicInterventionE/C/F/TAF; Ledipasvir-SofosbuvirPhasePhase 3Registry statusCompletedSafety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women
NCT02652624 · start 2016-02-19
Registered record
- Registry ID
- NCT02652624
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF; E/C/F/TDF; ATV; RTV; FTC/TDF; B/F/TAF
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2016-02-19
- Completion
- 2018-11-26
- Enrolment
- 472
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1 InfectionInterventionE/C/F/TAF; E/C/F/TDF; ATV; RTV +2 morePhasePhase 3Registry statusCompletedElvitegravir (EVG) Cerebrospinal Fluid (CSF) Pharmacokinetics in HIV-Infected Individuals
NCT02251236 · start 2016-01
Registered record
- Registry ID
- NCT02251236
- Conditions
- HIV
- Interventions
- Stribild; Genvoya
- Study type
- INTERVENTIONAL
- Phase
- Not applicable
- Registry status
- Completed
- Start
- 2016-01
- Completion
- 2017-01-18
- Enrolment
- 14
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIVInterventionStribild; GenvoyaPhaseNot applicableRegistry statusCompletedStudy to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I
NCT02616029 · start 2015-12-17
Registered record
- Registry ID
- NCT02616029
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-12-17
- Completion
- 2019-07-11
- Enrolment
- 66
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1 InfectionInterventionE/C/F/TAFPhasePhase 3Registry statusCompletedStudy to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults
NCT02603107 · start 2015-11-20
Registered record
- Registry ID
- NCT02603107
- Conditions
- HIV-1 Infection
- Interventions
- RTV; ATV; DRV; COBI; ATV/co; DRV/co; FTC/TDF; ABC/3TC; B/F/TAF
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-11-20
- Completion
- 2019-12-23
- Enrolment
- 578
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1 InfectionInterventionRTV; ATV; DRV; COBI +5 morePhasePhase 3Registry statusCompletedSafety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults
NCT02605954 · start 2015-11-18
Registered record
- Registry ID
- NCT02605954
- Conditions
- HIV-1 Infection
- Interventions
- E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2015-11-18
- Completion
- 2018-01-24
- Enrolment
- 275
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionHIV-1 InfectionInterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral AgentPhasePhase 3Registry statusCompleted